Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis

Main Article Content

James Q. Del Rosso
JDR Dermatology Research, Las Vegas, NV, USA

Pearl Kwong
Solutions Through Advanced Research, Jacksonville, FL, USA

Iftikhar Hussain
Vital Prospects Clinical Research Institute, Tulsa, OK, USA

Sebastien Barbarot
Department of Dermatology, Centre Hospitalier Universitaire de Nantes, Nantes, France

Jose Manuel Carrascosa
Department of Dermatology, Hospital Universitari Germans Trias I Pujol. IGTP, Barcelona, Spain

Maria Jose Rueda
Eli Lilly and Company, Indianapolis, IN, USA

Amber Reck Atwater
Eli Lilly and Company, Indianapolis, IN, USA

Hany Elmaraghy
Eli Lilly and Company, Indianapolis, IN, USA

Luna Sun
Eli Lilly and Company, Indianapolis, IN, USA

Sherry Chen
Tigermed, Somerset, NJ, USA

Chitra Natalie
Eli Lilly and Company, Indianapolis, IN, USA

Stephan Weidinger
Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany

Keywords

Lebrikizumab, Atopic Dermatitis

References

1. Tsoi LC et al. J Invest Dermatol. 2019; 139:1480-9.

2. Ultsch M et al. J Mol Biol. 2013; 425:1330-9.

3. Okragly A, et al. Presented at the Inflammatory Skin Disease Summit, New York, 2021

4. Silverberg J et al. Presented at American Academy of Dermatology (AAD), Virtual Meeting Experience, 2022

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.147

Article Details

How to Cite
Del Rosso, J., Kwong, P., Hussain, I., Barbarot, S., Carrascosa, J., Rueda, M., Atwater, A., Elmaraghy, H., Sun, L., Chen, S., Natalie, C., & Weidinger, S. (2023). Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(2), s147. https://doi.org/10.25251/skin.7.supp.147
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>